Psoriasis is the result of uncontrolled keratinocyte proliferation, and its pathogenesis
involves the dysregulation of the immune system. The interplay among cytokines released …

Since its discovery, the Janus kinase-signal transduction and activation of transcription (JAK-
STAT) pathway has become recognized as a central mediator of widespread and varied …

Abstract Background Targeting interleukin-23 (IL-23) is an important therapeutic strategy for
Crohn's disease (CD). Aims This systematic review and meta-analysis assessed the efficacy …

Recently, there have been impressive advancements in understanding of the immune
mechanisms underlying cutaneous inflammatory diseases. To understand these diseases …

Psoriasis is a chronic inflammatory skin disease, in which molecular and cellular changes
retain following clinical resolution of psoriatic lesions, a form of disease memory ('molecular …

Objective To investigate serum protein expression in participants with psoriatic arthritis (PsA)
and changes after guselkumab treatment. Methods Participants with PsA were treated with …

Guselkumab, a subcutaneously administered fully human IgG1 monoclonal antibody that
selectively inhibits the p19 subunit of interleukin 23, is approved in both the USA and the EU …

Background PERSIST was a prospective, non‐interventional, real‐world study of
guselkumab and ustekinumab in adult patients with moderate‐to‐severe plaque psoriasis in …

Background For patients with psoriasis, discontinuation of biologics following remission has
become more common in daily practice. Objective We aimed to identify predictors and …

In the literature there is no consensus on the correlation between early systemic intervention
and better treatment response in psoriasis. Here we present data on the impact of disease …